Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.
about
Atacicept: targeting B cells in multiple sclerosisCurrent and emerging treatment options in the management of lupusCytokine-Defined B Cell Responses as Therapeutic Targets in Multiple SclerosisKey issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implicationsB-cell survival factors in autoimmune rheumatic disordersFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsThe rationale for BAFF inhibition in systemic lupus erythematosusProfile of atacicept and its potential in the treatment of systemic lupus erythematosusEfficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.Sjogren's syndrome: Review of the aetiology, Pathophysiology & Potential therapeutic interventions.Promising treatments of tomorrow for multiple sclerosis.Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.Antibody-based therapeutics to watch in 2011.Treatment of systemic lupus erythematosus with epratuzumab.Current and novel therapeutics in the treatment of systemic lupus erythematosusRenal involvement in autoimmune connective tissue diseases.Galectin-9 ameliorates clinical severity of MRL/lpr lupus-prone mice by inducing plasma cell apoptosis independently of Tim-3.No evidence that soluble TACI induces signalling via membrane-expressed BAFF and APRIL in myeloid cells.Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies.Cytokine disturbances in systemic lupus erythematosus.The discovery and development of belimumab: the anti-BLyS-lupus connectionDispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice.Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLETreatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.Metabolic regulation of organelle homeostasis in lupus T cellsInhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).Advances in human B cell phenotypic profiling.Contemporary treatment of systemic lupus erythematosus: an update for clinicians.Belimumab in systemic lupus erythematosus: an update for clinicians.B-cell activating factor targeted therapy and lupus.Clinical targeting of the TNF and TNFR superfamiliesBiologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosusThe Janus of lupus--benefits and risks with B-cell therapy.The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects.
P2860
Q24628925-86815572-32DD-433D-B19A-4289C85C0843Q26741266-5CD61141-CA9F-4128-9516-9B05945B4E5DQ26771459-415F7E7F-53B1-4774-86FD-FE2E3B0FBD9DQ26775756-65FE2E8D-CC01-4098-922F-BD69C7A8C055Q26796484-2607DE3C-4ADA-4307-B0F4-EB725D8BD20FQ26822421-52AD2924-9670-4F74-9F50-4F6DB660458CQ26827373-F7C23D36-9562-488D-A3D7-F3FC9AC72B5EQ26849719-0ED9E819-ED9B-464A-9852-30D3CC31FB44Q30832522-976E2E25-9808-4ECE-B84E-E6033B529D31Q33385389-D02FEE87-2FBE-480C-9D1D-203F5B9D593FQ33619691-2388305B-35B5-47FF-A8ED-368003A2134EQ33670947-8990713B-9714-4C3B-B205-0AE6124561CAQ33698040-5B159A67-7A6E-4823-BE98-ECFDBC7C7618Q34159016-1C45FAB4-49C4-461B-A3FF-D98C2D6C7F6EQ34245983-9E47CD8F-E7EA-4C77-9165-4F672BEC49ABQ34570079-6B571A58-9629-4818-80FF-6B8CCFE40824Q34580559-C1F9F7A8-A6E7-4965-828F-5554E03F0805Q34648851-5F9270FA-FD84-4EF6-9F4C-89A565C4556DQ34654954-59908A38-164A-47D3-856F-271E5BF9CE45Q34667834-DB9CDDCE-85F6-4965-9E95-53107BAA1AC7Q34688769-65CFD6D9-A109-482F-92FB-1CE225295F92Q35031692-670048FB-F0A5-44F5-AFD5-52D206DE6BE3Q35456519-95D55997-75DA-4C2B-A04E-4441558427F9Q35617573-A84BC80A-22BB-4797-9389-78F94C234E63Q35691272-4B8CC066-0A80-491B-936E-39E6515A1D91Q35798968-2CDA3687-8A28-4397-8F78-9BAAF8978689Q35829864-1F9F4F5D-7BE7-4219-893F-F0DA62179698Q35986113-79F8B1D5-BADD-4A5C-B251-7ACC587E8209Q36085018-067EBFF6-B9AF-4371-8DE5-69651A9D2E03Q36177195-5B38B56C-E405-4089-8479-6F30B9AF1B43Q36271212-B33C13A1-34BA-4870-B860-86A413FFFEB6Q36307080-036DC4DF-B572-4688-B153-BAD50BA0A97BQ36443689-F1F03C59-C5E2-4678-A7EF-A0E4D9100296Q36443781-A1FC0E1C-1A3D-4A82-8DB8-C1B3F57C97D8Q36504641-535EC0FB-4881-447B-A518-FAC8050BA7F2Q36762882-B3C00982-136B-4B26-A48D-1206FBED05D5Q36993242-EEF1CB79-CC03-4164-BCA5-39D9A218842DQ37168037-A48F53AA-9F58-43CD-9A30-589C39704D6EQ37170754-83A5319D-F778-44C6-AB29-29D9D6D0E770Q37270803-7BCB5B06-9902-4172-85AA-51F95C685A16
P2860
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Reduced B lymphocyte and immun ...... rolled, dose-escalating trial.
@en
Reduced B lymphocyte and immun ...... rolled, dose-escalating trial.
@nl
type
label
Reduced B lymphocyte and immun ...... rolled, dose-escalating trial.
@en
Reduced B lymphocyte and immun ...... rolled, dose-escalating trial.
@nl
prefLabel
Reduced B lymphocyte and immun ...... rolled, dose-escalating trial.
@en
Reduced B lymphocyte and immun ...... rolled, dose-escalating trial.
@nl
P2093
P356
P1476
Reduced B lymphocyte and immun ...... rolled, dose-escalating trial.
@en
P2093
Arthur Kavanaugh
Claudia Pena-Rossi
Daniel Wallace
David Wofsy
Eliza Chakravarty
Emmanuelle Vincent
Kenneth Kalunian
Maria Dall'Era
Mark Genovese
Michael Weisman
P304
P356
10.1002/ART.23047
P577
2007-12-01T00:00:00Z